Victory Capital Management Inc. lessened its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 8.8% during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 3,612 shares of the biopharmaceutical company’s stock after selling 350 shares during the period. Victory Capital Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $1,615,000 at the end of the most recent quarter.
Other large investors also recently added to or reduced their stakes in the company. Janus Henderson Group PLC raised its stake in Regeneron Pharmaceuticals by 15,495.4% in the second quarter. Janus Henderson Group PLC now owns 1,562,970 shares of the biopharmaceutical company’s stock valued at $767,637,000 after buying an additional 1,552,948 shares during the last quarter. Jennison Associates LLC raised its stake in shares of Regeneron Pharmaceuticals by 74.1% in the second quarter. Jennison Associates LLC now owns 1,292,863 shares of the biopharmaceutical company’s stock worth $634,977,000 after purchasing an additional 550,247 shares during the last quarter. FMR LLC raised its stake in shares of Regeneron Pharmaceuticals by 6.3% in the second quarter. FMR LLC now owns 7,039,884 shares of the biopharmaceutical company’s stock worth $3,457,569,000 after purchasing an additional 416,192 shares during the last quarter. TIAA CREF Investment Management LLC raised its stake in shares of Regeneron Pharmaceuticals by 97.8% in the second quarter. TIAA CREF Investment Management LLC now owns 485,336 shares of the biopharmaceutical company’s stock worth $238,368,000 after purchasing an additional 239,937 shares during the last quarter. Finally, PointState Capital LP purchased a new position in shares of Regeneron Pharmaceuticals in the second quarter worth about $78,199,000. Institutional investors own 66.67% of the company’s stock.
Several analysts recently commented on REGN shares. Canaccord Genuity set a $522.00 target price on Regeneron Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, August 14th. Citigroup reissued a “buy” rating and issued a $575.00 price objective on shares of Regeneron Pharmaceuticals in a report on Thursday, September 7th. Credit Suisse Group reissued a “buy” rating and issued a $485.00 price objective on shares of Regeneron Pharmaceuticals in a report on Monday, September 11th. UBS lowered their price target on Regeneron Pharmaceuticals from $535.00 to $500.00 and set a “buy” rating on the stock in a research note on Thursday, September 21st. Finally, Guggenheim reaffirmed a “buy” rating and issued a $540.00 price target on shares of Regeneron Pharmaceuticals in a research note on Monday, October 23rd. Two analysts have rated the stock with a sell rating, sixteen have given a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $467.84.
Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported $3.99 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.83 by $0.16. The business had revenue of $1.50 billion for the quarter, compared to analysts’ expectations of $1.45 billion. Regeneron Pharmaceuticals had a return on equity of 25.73% and a net margin of 23.17%. The business’s revenue was up 23.0% on a year-over-year basis. During the same quarter last year, the firm earned $3.13 earnings per share. sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 13.55 EPS for the current year.
In other news, Director Charles A. Baker sold 2,000 shares of the firm’s stock in a transaction dated Friday, September 29th. The stock was sold at an average price of $450.00, for a total transaction of $900,000.00. Following the completion of the sale, the director now directly owns 11,000 shares in the company, valued at $4,950,000. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Michael S. Brown sold 1,500 shares of the firm’s stock in a transaction dated Thursday, October 5th. The shares were sold at an average price of $475.00, for a total value of $712,500.00. The disclosure for this sale can be found here. Company insiders own 10.80% of the company’s stock.
WARNING: This piece of content was originally reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright legislation. The correct version of this piece of content can be read at https://stocknewstimes.com/2017/12/06/victory-capital-management-inc-sells-350-shares-of-regeneron-pharmaceuticals-inc-regn.html.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.